A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Trial Profile

A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Fingolimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFORMS
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 27 Jun 2017 Results assessing the effect of Fingolimod on Neurofilament Light Chain Blood Levels in patients from two phase III trials (FREEDOMS, TRANSFORMS; n=387) compared with healthy subjects (n=35), presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results of post hoc analysis performed on the 7-year data from TRANSFORMS core and extension studies, presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results of 7 year analysis of data from TRANSFORM study presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top